Joseph Capper Purchases 50,000 Shares of TELA Bio (NASDAQ:TELA) Stock

Key Points

• Director Joseph Capper purchased 50,000 TELA Bio shares at an average price of $1.06, investing $53,000 and increasing his direct ownership by 91.2% to 104,827 shares.
• TELA Bio shares rose 8.3% to $1.18, but the company reported a quarterly loss of $0.20 per share and revenue of $19.29 million, both weaker than analyst expectations.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and a $2.20 price target; institutional investors own 94.35% of the company.

TELA Bio, Inc. (NASDAQ:TELA - Get Free Report) Director Joseph Capper bought 50,000 shares of the company's stock in a transaction dated Tuesday, September 15th. The stock was acquired at an average price of $1.06 per share, for a total transaction of $53,000.00. Following the acquisition, the director directly owned 104,827 shares in the company, valued at $111,116.62. This trade represents a 91.20% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

TELA Bio Stock Up 8.3%

Shares of TELA stock traded up $0.09 during trading on Wednesday, hitting $1.18. 453,536 shares of the company were exchanged, compared to its average volume of 184,035. The company has a debt-to-equity ratio of 8.82, a quick ratio of 2.38 and a current ratio of 2.99. The firm has a market capitalization of $52.98 million, a price-to-earnings ratio of -1.53 and a beta of 1.36. The business's 50-day simple moving average is $0.78 and its 200 day simple moving average is $0.79. TELA Bio, Inc. has a twelve month low of $0.50 and a twelve month high of $1.69.

TELA Bio (NASDAQ:TELA - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). TELA Bio had a negative net margin of 51.53% and a negative return on equity of 1,320.81%. The company had revenue of $19.29 million during the quarter, compared to analyst estimates of $20.01 million. As a group, analysts forecast that TELA Bio, Inc. will post -0.76 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of TELA Bio in a report on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $2.20.

Hedge Funds Weigh In On TELA Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC bought a new stake in TELA Bio in the second quarter worth approximately $4,420,586. Stonepine Capital Management LLC acquired a new stake in shares of TELA Bio in the 2nd quarter valued at $1,996,820. BlackRock Inc. acquired a new stake in shares of TELA Bio in the 2nd quarter valued at $281,000. UP Strategic Wealth Investment Advisors LLC bought a new stake in TELA Bio in the second quarter worth $91,000. Finally, Perkins Capital Management Inc. boosted its holdings in TELA Bio by 1.5% in the first quarter. Perkins Capital Management Inc. now owns 1,418,328 shares of the company's stock worth $879,000 after purchasing an additional 20,910 shares in the last quarter. Institutional investors own 94.35% of the company's stock.

About TELA Bio

TELA Bio, Inc NASDAQ: TELA is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body's natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company's product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.